IL-8 Antibody, pAb, Goat
- Known as:
- Interleukin-8 Antibody, pAb, Goat
- Catalog number:
- A00158-40
- Product Quantity:
- 40,0μg
- Category:
- -
- Supplier:
- Genscript
- Gene target:
- IL-8 Antibody pAb Goat
Related genes to: IL-8 Antibody, pAb, Goat
- Gene:
- CXCL8 NIH gene
- Name:
- C-X-C motif chemokine ligand 8
- Previous symbol:
- IL8
- Synonyms:
- SCYB8, LUCT, LECT, MDNCF, TSG-1, IL-8, NAP-1, 3-10C, MONAP, AMCF-I, LYNAP, NAF, b-ENAP, GCP-1, K60, GCP1, NAP1
- Chromosome:
- 4q13.3
- Locus Type:
- gene with protein product
- Date approved:
- 1989-06-30
- Date modifiied:
- 2016-10-05
- Gene:
- CXCR1 NIH gene
- Name:
- C-X-C motif chemokine receptor 1
- Previous symbol:
- CMKAR1, IL8RA
- Synonyms:
- CKR-1, CDw128a, CD181
- Chromosome:
- 2q35
- Locus Type:
- gene with protein product
- Date approved:
- 1992-11-09
- Date modifiied:
- 2016-03-14
- Gene:
- CXCR2 NIH gene
- Name:
- C-X-C motif chemokine receptor 2
- Previous symbol:
- IL8RB
- Synonyms:
- CMKAR2, CD182
- Chromosome:
- 2q35
- Locus Type:
- gene with protein product
- Date approved:
- 1991-08-19
- Date modifiied:
- 2016-03-14
- Gene:
- CXCR2P1 NIH gene
- Name:
- C-X-C motif chemokine receptor 2 pseudogene 1
- Previous symbol:
- IL8RBP, CXCR2P
- Synonyms:
- -
- Chromosome:
- 2q35
- Locus Type:
- pseudogene
- Date approved:
- 1992-11-27
- Date modifiied:
- 2016-03-14
Related products to: IL-8 Antibody, pAb, Goat
Related articles to: IL-8 Antibody, pAb, Goat
- Inflammatory Bowel Disease (IBD), including Ulcerative Colitis and Crohn's Disease, is characterized by chronic intestinal inflammation, neutrophil infiltration and elevated pro-inflammatory cytokines like Interleukin-8 (IL-8). While pro-inflammatory mechanisms are well-studied, the contribution of intrinsic inhibitory immune checkpoints to IBD pathogenesis is less understood. This study aimed to assess the expression and function of Signal Inhibitory Receptor on Leukocytes-1 (SIRL-1) in IBD and to evaluate the diagnostic utility of the SIRL-1/IL-8 ratio. - Source: PubMed
Publication date: 2026/04/17
Wang ZhengzhengLi ShanTan QiSang JianminXu ZhenDing XueweiYao XiaoyanChen NianzhenYu ShanshanZong MingLu YingZhong LanFan Lieying - : (SJC), as a traditional medicinal plant, has garnered significant attention for its extensive pharmacological activities. However, a systematic investigation of its comprehensive chemical profile and the underlying mechanisms in colorectal cancer (CRC) remains to be elucidated. This study aims to elucidate the active compounds and targets responsible for the anti-colorectal cancer effects of the aqueous extract of SJC. An integrated strategy was employed. The chemical profile of the SJC aqueous extract was analyzed by UPLC-MS/MS. Its anticancer activities, including effects on cell proliferation, migration, and apoptosis, were evaluated using the HCT-116 CRC cell line. An integrated transcriptomic and bioinformatic approach, followed by protein-protein interaction (PPI) network analysis, was used to identify key molecular pathways and targets. Finally, molecular docking and cellular assays were performed to screen for potential bioactive compounds. A total of 60 natural compounds were tentatively identified in SJC. SJC inhibited the proliferation, migration, and invasion of HCT-116 colorectal cancer cells. Through combined transcriptomic and bioinformatic analysis, four candidate key genes were initially identified. Further PPI network analysis prioritized CXCL8 as a key candidate among the four candidate targets. Molecular docking against CXCL8, together with subsequent cellular experiments, validated naringenin as a potential bioactive constituent contributing to the anti-CRC activity of SJC. This study provides a comprehensive chemical profile of SJC and offers significant insights into its potential anticancer mechanisms in CRC by identifying candidate targets and a potential bioactive constituent. While these findings are preliminary and require further experimental validation through additional CRC cell lines and in vivo models, they establish a solid foundation for future research into the therapeutic applications of SJC for colorectal cancer. These planned studies will help to further elucidate the underlying mechanisms and assess the translational potential of SJC. - Source: PubMed
Publication date: 2026/04/02
Li Long-ZhuLi Xin-YueWang Zi-YuanMa Tian-QiWu Yan-ChaoLi Hui-Jing - Dengue fever is one of the most common mosquito-borne viral infections, with severe cases characterized by plasma leakage, hemorrhage, and multi-organ involvement. Identification of dengue serotypes and reliable biomarkers is essential for predicting disease progression and guiding timely interventions. - Source: PubMed
Publication date: 2026/04/17
Sivasubramanian KumarBharath Rudrappan RajVajravelu Leela KakithakaraKumar D MadanPamarthi Jayakrishna - Immune thrombocytopenia (ITP) is an autoimmune disease. Megakaryocyte dysfunction caused by autoimmune response can lead to thrombocytopenia, and the underlying mechanism is still unclear. Single-cell sequencing analysis revealed the heterogeneity of CD34 + HSPCs in bone marrow between ITP patients and healthy groups. Pre-B cell population 1 (pre-B1) showed a significantly lower percentage contribution in ITP groups, and the underlying mechanism involves cell cycle-, cell apoptosis- and cell death-related pathways. The number of eosinophil-basophil mast cell progenitors (EBMPs) is significantly increased in ITP patients and the DEGs of the EBMPs in ITP patients were significantly enriched in immune-related pathways. Further, immunofluorescent staining and Western blot assay highlight C-X-C Motif Chemokine Ligand 8 (CXCL8) and Interferon Regulatory Factor 1 (IRF1) expression were significantly increased in the EBMPs of ITP patients. Furthermore, cell-cell communication analysis identified an impaired LGALS9-CD44 axis between EBMP cells and MkP1 cells in ITP patients, suggesting that targeting the LGALS9-CD44 interaction might hold promise as a therapeutic approach for ITP. Our observations indicate that ITP patients exhibit an elevated proportion of EBMP cells alongside a reduced proportion of pre-B1 cells. CXCL8 and IRF1 are potentially associated with EBMP cell dysfunction and the ITP disease process. Furthermore, the diminished LGALS9-CD44 axis between EBMP and MkP1 cells may contribute to ITP progression, suggesting a direction for future therapeutic investigation. - Source: PubMed
Publication date: 2026/04/15
Xie MeiDeng HaimeiLiu FangjieXiao WeiXu XiaojunXie RongliSun Tiantian - : We previously pioneered a multigene mRNA test, qMIDS, validated through an international multicohort study with geographically and ethnically diverse oral squamous cell carcinoma (OSCC) patients from Europe and Asia. This study aimed to repurpose the qMIDS test for nasopharyngeal carcinoma (NPC). A molecular test independent of Epstein-Barr virus (EBV) status would be clinically useful for risk stratification in NPC patients with undetectable or low levels of EBV. : This study investigated a Chinese cohort of 62 participants (18 donated normal nasopharyngeal mucosa (NPM) and 44 donated NPC tissue samples). Messenger RNA levels of 16 genes in each sample were quantified using the qPCR method, and an algorithm computed a malignancy index for cancer risk stratification. : We identified a unique 10-gene panel (containing eight target genes, namely NEK2, INHBA, FOXM1, TOP2A, BIRC5, CXCL8, NR3C1, and IVL, relative to two reference genes, YAP1 and POLR2A, collectively named qMIDS) that demonstrated the best overall diagnostic performance in segregating NPM from NPC, with AUC = 0.909 and positive/negative predictive values of 91% PPV and 78% NPV, respectively. Furthermore, we demonstrated prognostic value of qMIDS in segregating NPM from NPC stage III + IV, with AUC = 0.936, 92% PPV, and 84% NPV. : Here, we present a simple qPCR-based 10-gene mRNA test, qMIDS, with potential clinical utilities for rapid (1 h) prognostic stratification of NPC. Further studies involving geographically and ethnically independent NPC cohorts would be needed to validate the clinical use of qMIDS in non-endemic NPC populations. - Source: PubMed
Publication date: 2026/04/09
Liang YingyingMo ZhiwenTeh Muy-Teck